Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2023	00054252731	Lithium Carbonate Oral Capsule 300 MG, 1 Bottle of 1000 Capsules	Brand	FDA	01/06/2023	143.71	213.81	None	Non-innovator Multiple Source Drug	None	1	Increased costs incurred with the acquisition of raw materials, rate of inflation and ongoing changes in the competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2023	00054452731	Lithium Carbonate Oral Tablet 300 MG, 1 Bottle of 1000 Tabs	Brand	FDA	01/06/2023	34.41	206.44	None	Non-innovator Multiple Source Drug	None	1	Increased costs incurred with the acquisition of raw materials, rate of inflation and ongoing changes in the competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2023	00641605010	LORazepam Injection Solution 2 MG/ML 10 vials	Brand	FDA	06/21/2023	38.66	106.46	None	Innovator Multiple Source Drug	None	1	This Product was last increased by Hikma in 2012. Factors which led to this WAC increase included a double-digit increase in the raw materials, as well costs associated with validating a second supplier of such raw materials. Additionally, increased costs associated with the rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics played a part.	None	Not applicable.	None	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2023	75987008010	Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial	Brand	FDA	07/28/2023	655.36	27960.56	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for Krystexxa is not publicly available.